A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

A phase 1b/2, three‐month study of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), was conducted in participants with haemophilia A or B, with or without inhibitors. Participants assigned to four cohorts received escalating weekly doses based on inhibitor s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlangu, Johnny N., Lamas, Jose Luis, Morales, Juan Cristobal, Malan, Daniel R., Šalek, Silva Zupančić, Wang, Michael, Boggio, Lisa N., Hegemann, Inga, Mital, Andrzej, Cardinal, Matthew, Zhu, Tong, Sun, Pengling, Arkin, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Platelets, Thrombosis and Haemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286764/
https://www.ncbi.nlm.nih.gov/pubmed/35999026
http://dx.doi.org/10.1111/bjh.18420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286764/
https://www.ncbi.nlm.nih.gov/pubmed/35999026
http://dx.doi.org/10.1111/bjh.18420

Ejemplares similares